vs
博士伦（BLCO）与威德福国际（WFRD）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是威德福国际的1.2倍（$1.4B vs $1.2B），威德福国际净利率更高（9.5% vs -4.1%，领先13.6%），博士伦同比增速更快（9.8% vs -8.3%），威德福国际自由现金流更多（$85.0M vs $60.0M），过去两年博士伦的营收复合增速更高（13.1% vs -9.5%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
威德福国际是一家美国跨国油田服务企业，总部位于美国，业务覆盖全球75个国家的油气产区，为油气井的钻探、评估、完井、生产及修井作业提供专业技术设备与相关服务，在全球油田服务领域拥有广泛布局。
BLCO vs WFRD — 直观对比
营收规模更大
BLCO
是对方的1.2倍
$1.2B
营收增速更快
BLCO
高出18.1%
-8.3%
净利率更高
WFRD
高出13.6%
-4.1%
自由现金流更多
WFRD
多$25.0M
$60.0M
两年增速更快
BLCO
近两年复合增速
-9.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.2B |
| 净利润 | $-58.0M | $109.0M |
| 毛利率 | — | — |
| 营业利润率 | 8.0% | 10.7% |
| 净利率 | -4.1% | 9.5% |
| 营收同比 | 9.8% | -8.3% |
| 净利润同比 | -1833.3% | -21.6% |
| 每股收益（稀释后） | $-0.16 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOWFRD
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.2B | $1.4B | ||
| Q2 24 | $1.2B | $1.4B |
净利润BLCOWFRD
| Q1 26 | — | $109.0M | ||
| Q4 25 | $-58.0M | $138.0M | ||
| Q3 25 | $-28.0M | $81.0M | ||
| Q2 25 | $-62.0M | $136.0M | ||
| Q1 25 | $-212.0M | $76.0M | ||
| Q4 24 | $-3.0M | $112.0M | ||
| Q3 24 | $4.0M | $157.0M | ||
| Q2 24 | $-151.0M | $125.0M |
营业利润率BLCOWFRD
| Q1 26 | — | 10.7% | ||
| Q4 25 | 8.0% | 15.4% | ||
| Q3 25 | 7.4% | 14.4% | ||
| Q2 25 | -0.9% | 19.7% | ||
| Q1 25 | -7.3% | 11.9% | ||
| Q4 24 | 6.8% | 14.8% | ||
| Q3 24 | 3.6% | 17.2% | ||
| Q2 24 | 2.1% | 18.8% |
净利率BLCOWFRD
| Q1 26 | — | 9.5% | ||
| Q4 25 | -4.1% | 10.7% | ||
| Q3 25 | -2.2% | 6.6% | ||
| Q2 25 | -4.9% | 11.3% | ||
| Q1 25 | -18.6% | 6.4% | ||
| Q4 24 | -0.2% | 8.4% | ||
| Q3 24 | 0.3% | 11.1% | ||
| Q2 24 | -12.4% | 8.9% |
每股收益（稀释后）BLCOWFRD
| Q1 26 | — | $1.49 | ||
| Q4 25 | $-0.16 | $1.91 | ||
| Q3 25 | $-0.08 | $1.12 | ||
| Q2 25 | $-0.18 | $1.87 | ||
| Q1 25 | $-0.60 | $1.03 | ||
| Q4 24 | $-0.00 | $1.53 | ||
| Q3 24 | $0.01 | $2.06 | ||
| Q2 24 | $-0.43 | $1.66 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $1.0B |
| 总债务越低越好 | $5.0B | $1.5B |
| 股东权益账面价值 | $6.4B | $1.8B |
| 总资产 | $14.0B | — |
| 负债/权益比越低杠杆越低 | 0.78× | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资BLCOWFRD
| Q1 26 | — | $1.0B | ||
| Q4 25 | $383.0M | $987.0M | ||
| Q3 25 | $310.0M | $967.0M | ||
| Q2 25 | $266.0M | $943.0M | ||
| Q1 25 | $202.0M | $873.0M | ||
| Q4 24 | $305.0M | $916.0M | ||
| Q3 24 | $329.0M | $920.0M | ||
| Q2 24 | $285.0M | $862.0M |
总债务BLCOWFRD
| Q1 26 | — | $1.5B | ||
| Q4 25 | $5.0B | $1.5B | ||
| Q3 25 | $5.0B | $1.5B | ||
| Q2 25 | $5.0B | $1.6B | ||
| Q1 25 | $4.8B | $1.6B | ||
| Q4 24 | $4.8B | $1.6B | ||
| Q3 24 | $4.6B | $1.6B | ||
| Q2 24 | $4.6B | $1.6B |
股东权益BLCOWFRD
| Q1 26 | — | $1.8B | ||
| Q4 25 | $6.4B | $1.7B | ||
| Q3 25 | $6.4B | $1.6B | ||
| Q2 25 | $6.4B | $1.5B | ||
| Q1 25 | $6.4B | $1.4B | ||
| Q4 24 | $6.5B | $1.3B | ||
| Q3 24 | $6.6B | $1.3B | ||
| Q2 24 | $6.5B | $1.2B |
总资产BLCOWFRD
| Q1 26 | — | — | ||
| Q4 25 | $14.0B | $5.2B | ||
| Q3 25 | $13.8B | $5.3B | ||
| Q2 25 | $13.8B | $5.1B | ||
| Q1 25 | $13.4B | $5.1B | ||
| Q4 24 | $13.5B | $5.2B | ||
| Q3 24 | $13.5B | $5.2B | ||
| Q2 24 | $13.3B | $5.1B |
负债/权益比BLCOWFRD
| Q1 26 | — | 0.84× | ||
| Q4 25 | 0.78× | 0.86× | ||
| Q3 25 | 0.77× | 0.94× | ||
| Q2 25 | 0.77× | 1.04× | ||
| Q1 25 | 0.76× | 1.17× | ||
| Q4 24 | 0.74× | 1.26× | ||
| Q3 24 | 0.70× | 1.21× | ||
| Q2 24 | 0.71× | 1.33× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $136.0M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $85.0M |
| 自由现金流率自由现金流/营收 | 4.3% | 7.4% |
| 资本支出强度资本支出/营收 | 5.4% | 4.7% |
| 现金转化率经营现金流/净利润 | — | 1.25× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $470.0M |
8季度趋势，按日历期对齐
经营现金流BLCOWFRD
| Q1 26 | — | $136.0M | ||
| Q4 25 | $136.0M | $268.0M | ||
| Q3 25 | $137.0M | $138.0M | ||
| Q2 25 | $35.0M | $128.0M | ||
| Q1 25 | $-25.0M | $142.0M | ||
| Q4 24 | $22.0M | $249.0M | ||
| Q3 24 | $154.0M | $262.0M | ||
| Q2 24 | $15.0M | $150.0M |
自由现金流BLCOWFRD
| Q1 26 | — | $85.0M | ||
| Q4 25 | $60.0M | $217.0M | ||
| Q3 25 | $63.0M | $94.0M | ||
| Q2 25 | $-54.0M | $74.0M | ||
| Q1 25 | $-135.0M | $65.0M | ||
| Q4 24 | $-70.0M | $149.0M | ||
| Q3 24 | $94.0M | $184.0M | ||
| Q2 24 | $-57.0M | $88.0M |
自由现金流率BLCOWFRD
| Q1 26 | — | 7.4% | ||
| Q4 25 | 4.3% | 16.8% | ||
| Q3 25 | 4.9% | 7.6% | ||
| Q2 25 | -4.2% | 6.1% | ||
| Q1 25 | -11.9% | 5.4% | ||
| Q4 24 | -5.5% | 11.1% | ||
| Q3 24 | 7.9% | 13.1% | ||
| Q2 24 | -4.7% | 6.3% |
资本支出强度BLCOWFRD
| Q1 26 | — | 4.7% | ||
| Q4 25 | 5.4% | 4.0% | ||
| Q3 25 | 5.8% | 3.6% | ||
| Q2 25 | 7.0% | 4.5% | ||
| Q1 25 | 9.7% | 6.5% | ||
| Q4 24 | 7.2% | 7.5% | ||
| Q3 24 | 5.0% | 5.5% | ||
| Q2 24 | 5.9% | 4.4% |
现金转化率BLCOWFRD
| Q1 26 | — | 1.25× | ||
| Q4 25 | — | 1.94× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 1.87× | ||
| Q4 24 | — | 2.22× | ||
| Q3 24 | 38.50× | 1.67× | ||
| Q2 24 | — | 1.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
WFRD
| Middle East/North Africa/Asia | $556.0M | 48% |
| Other | $360.0M | 31% |
| Europe/Sub-Sahara Africa/Russia | $236.0M | 20% |
